Key Drivers
- Strong cash conversion
- High balance leverage
- Tight liquidity
AIAI Summary
IQV should be viewed less as a pure growth rerating and more as a cash-generative healthcare infrastructure name with a balance-sheet overhang: raised guidance and strong free cash flow keep the thesis intact, but high leverage, weak liquidity, and negative working capital cap upside unless deleveraging improves and the stock holds its new low-190s support.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash conversion
- •High balance leverage
- •Tight liquidity
IQV delivers strong profitability and cash flow, but high leverage, weak liquidity, and heavy intangibles make the balance sheet the main risk.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Support breakout
- •Stretch risk
IQV has posted a strong last month uptrend with higher highs/lows and a breakout above $193–$194 support, but the rally is stretched and may pause or consolidate before extending higher.
Sharp mid-June drop from $186.82 to $167.77 shows notable volatility risk
Sentiment & News
Key News Insights:
- •AI Expansion
- •Data Advantage
- •Liquidity Risk
IQVIA's recent coverage is constructive, driven by its AI/data advantages, partnership momentum, and strong cash flow, though weak liquidity remains the main risk.
The news flow supports a positive near-term sentiment and valuation case for IQVIA, but persistent balance-sheet concerns could limit upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings